Therapeutics Company Secures $3M Department of Defense Award For Pediatric Brain Cancer Trials
Breakthrough in Pediatric Brain Cancer Research: Plus Therapeutics Secures $3 Million DoD Award.
In an unprecedented move that signals a new era for cancer treatment, Plus Therapeutics, Inc., a trailblazer in the development of targeted radiotherapeutics, has been awarded a $3 million grant by the Department of Defense (DoD) through its Congressionally Directed Medical Research Programs (CDMRP). This substantial funding, set to kick off in Q3 2024, is earmarked for the expansion of clinical trials focused on pediatric brain cancer, offering a glimmer of hope for countless families and medical professionals grappling with this devastating diagnosis. $Plus Therapeutics (PSTV.US)$
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment